Online citations, reference lists, and bibliographies.

Association Between Use Of Non–Vitamin K Oral Anticoagulants With And Without Concurrent Medications And Risk Of Major Bleeding In Nonvalvular Atrial Fibrillation

Shang‐Hung Chang, I-Jun Chou, Yung‐Hsin Yeh, Meng-Jiun Chiou, Ming‐Shien Wen, Chi‐Tai Kuo, Lai‐Chu See, Chang‐Fu Kuo
Published 2017 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Importance Non–vitamin K oral anticoagulants (NOACs) are commonly prescribed with other medications that share metabolic pathways that may increase major bleeding risk. Objective To assess the association between use of NOACs with and without concurrent medications and risk of major bleeding in patients with nonvalvular atrial fibrillation. Design, Setting, and Participants Retrospective cohort study using data from the Taiwan National Health Insurance database and including 91 330 patients with nonvalvular atrial fibrillation who received at least 1 NOAC prescription of dabigatran, rivaroxaban, or apixaban from January 1, 2012, through December 31, 2016, with final follow-up on December 31, 2016. Exposures NOAC with or without concurrent use of atorvastatin; digoxin; verapamil; diltiazem; amiodarone; fluconazole; ketoconazole, itraconazole, voriconazole, or posaconazole; cyclosporine; erythromycin or clarithromycin; dronedarone; rifampin; or phenytoin. Main Outcomes and Measures Major bleeding, defined as hospitalization or emergency department visit with a primary diagnosis of intracranial hemorrhage or gastrointestinal, urogenital, or other bleeding. Adjusted incidence rate differences between person-quarters (exposure time for each person during each quarter of the calendar year) of NOAC with or without concurrent medications were estimated using Poisson regression and inverse probability of treatment weighting using the propensity score. Results Among 91 330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [SD, 10.8]; men, 55.8%; NOAC exposure: dabigatran, 45 347 patients; rivaroxaban, 54 006 patients; and apixaban, 12 886 patients), 4770 major bleeding events occurred during 447 037 person-quarters with NOAC prescriptions. The most common medications co-prescribed with NOACs over all person-quarters were atorvastatin (27.6%), diltiazem (22.7%), digoxin (22.5%), and amiodarone (21.1%). Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin with NOACs had a significant increase in adjusted incidence rates per 1000 person-years of major bleeding than NOACs alone: 38.09 for NOAC use alone vs 52.04 for amiodarone (difference, 13.94 [99% CI, 9.76-18.13]); 102.77 for NOAC use alone vs 241.92 for fluconazole (difference, 138.46 [99% CI, 80.96-195.97]); 65.66 for NOAC use alone vs 103.14 for rifampin (difference, 36.90 [99% CI, 1.59-72.22); and 56.07 for NOAC use alone vs 108.52 for phenytoin (difference, 52.31 [99% CI, 32.18-72.44]; P < .01 for all comparisons). Compared with NOAC use alone, the adjusted incidence rate for major bleeding was significantly lower for concurrent use of atorvastatin, digoxin, and erythromycin or clarithromycin and was not significantly different for concurrent use of verapamil; diltiazem; cyclosporine; ketoconazole, itraconazole, voriconazole, or posaconazole; and dronedarone. Conclusions and Relevance Among patients taking NOACs for nonvalvular atrial fibrillation, concurrent use of amiodarone, fluconazole, rifampin, and phenytoin compared with the use of NOACs alone, was associated with increased risk of major bleeding. Physicians prescribing NOAC medications should consider the potential risks associated with concomitant use of other drugs.
This paper references
Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin
J Stangier (2012)
10.1093/biomet/70.1.41
The central role of the propensity score in observational studies for causal effects
Paul R. Rosenbaum (1983)
10.1007/BF03256595
Coadministration of Dabigatran Etexilate and Atorvastatin
Joachim Stangier (2009)
10.1111/bcp.12055
A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.
Xavier Delavenne (2013)
10.1097/TP.0000000000000223
Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A.
Andreas Wannhoff (2014)
10.1124/dmd.113.053769
In Vitro Predictability of Drug-Drug Interaction Likelihood of P-Glycoprotein-Mediated Efflux of Dabigatran Etexilate Based on [I]2/IC50 Threshold
Wataru Kishimoto (2014)
10.1016/j.jacc.2016.11.007
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Marie D. Gerhard-Herman (2017)
10.1002/sim.1903
Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study.
Jared K Lunceford (2004)
10.1016/S0140-6736(13)62343-0
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff (2014)
10.3988/jcn.2013.9.3.139
Effect of 20 mg/day Atorvastatin: Recurrent Stroke Survey in Chinese Ischemic Stroke Patients with Prior Intracranial Hemorrhage
Wei-hua Jia (2013)
10.1161/STROKEAHA.112.655894
Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials.
James S. McKinney (2012)
10.1016/j.jacc.2016.06.028
Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation.
Sally Tamayo (2016)
10.1093/eurheartj/eht134
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.
Hein Heidbuchel (2013)
10.1093/eurheartj/ehw058
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary
Hein Heidbuchel (2017)
10.1016/j.jacc.2016.08.063
Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
Yi-Hsin Chan (2016)
10.1111/j.1538-7836.2011.04498.x
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.
K-H Liesenfeld (2011)
10.1136/bmj.315.7116.1151
Confounding and indication for treatment in evaluation of drug treatment for hypertension
Diederick E Grobbee (1997)
Novel anticoagulants—an update on the latest developments and management for Research Original Investigation Bleeding Risk in Nonvalvular AF on NOACs With vs Without Other Medications
B Green (2017)
10.1503/cmaj.150580
Bleeding associated with coadministration of rivaroxaban and clarithromycin
Michael Fralick (2016)
10.18549/PharmPract.2016.02.706
Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation
Yishen Wang (2016)
ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation
CB Granger (2011)
treated with cyclosporine A
KishimotoW (2014)
10.1016/j.jacc.2016.06.062
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Yi-Hsin Chan (2016)
10.1378/chest.10-0134
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
Ron Pisters (2010)
10.1161/CIRCULATIONAHA.116.021831
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Christian T. Ruff (2016)
10.1016/j.jacc.2016.11.062
Anticoagulation in Atrial Fibrillation: Is the Paradigm Really Shifting?
Prakash Deedwania (2017)
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of theARISTOTLE trial.BMJ. 2016;353:i2868
J Jaspers Focks (2016)
Novel anticoagulants—an update on the latest developments andmanagement for Research Original Investigation Bleeding Risk in Nonvalvular AF on NOACsWith vsWithout Other Medications
B Green (2017)
Cardiovascular , bleeding , andmortality risks of dabigatran in Asians with nonvalvular atrial fibrillation
YH Chan (2015)
10.1111/bcp.13092
Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
Dolly A. Parasrampuria (2016)
10.1111/ane.12540
High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis.
Awadh Kishor Pandit (2016)
10.1161/CIRCULATIONAHA.115.018544
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Jonathan P Piccini (2016)
10.1002/phar.1698
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
Barbara S Wiggins (2016)
10.1016/j.jacc.2014.07.967
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Greg C. Flaker (2014)
10.1016/0021-9681(87)90171-8
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
Mary E. Charlson (1987)
Novel anticoagulants—an update on the latest developments and management for Research Original Investigation Bleeding Risk in Nonvalvular AF on NOACs With vs Without Other Medications
B Green (2017)
10.1177/0091270010393342
Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
Joachim Stangier (2012)
10.1056/NEJMoa1107039
Apixaban versus warfarin in patients with atrial fibrillation.
Christopher B. Granger (2011)
10.1161/CIRCULATIONAHA.113.005119
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.
Sumeet S Chugh (2014)
10.1093/europace/euu225
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Jonas Bjerring Olesen (2015)
10.1136/bmj.h4052
Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis
Bao-Zhu Li (2015)
10.1111/bcp.12075
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Wolfgang Mueck (2013)
Thromboembolic, bleeding, andmortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation
Chan Y-H (2016)
10.1161/STROKEAHA.115.011476
Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Yi-Hsin Chan (2016)
10.1136/bmj.i2868
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
Jeroen Jaspers Focks (2016)
10.1161/CIRCULATIONAHA.115.016713
Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Stroke.
Gregory Y H Lip (2016)
10.1016/j.ahj.2006.02.013
Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
Shaul Atar (2006)
A newmethod of classifying prognostic comorbidity in longitudinal studies: development and validation
CharlsonME (1987)
10.2165/00129784-200909010-00006
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Joachim Stangier (2009)
RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation
SJ Connolly (2009)
10.1016/0895-4356(94)90129-5
Validation of a combined comorbidity index.
Mary E. Charlson (1994)
10.1136/bmj.h6223
Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis
John A Romley (2015)
10.1056/NEJMoa0905561
Dabigatran versus warfarin in patients with atrial fibrillation.
Stuart J. Connolly (2009)



This paper is referenced by
10.1002/cpt.1360
Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions
Arne Gessner (2019)
10.1272/MANMS.14.113
Distinguishing between Individual Direct Oral Anticoagulants on the Basis of their Specific Characteristics
Mami Sakurai (2018)
10.1016/J.CJCA.2019.02.001
Increased Risk of Bleeding in Elderly Patients Treated With Oral Anticoagulants and Angiotensin-Converting Enzyme Inhibitors.
Alice Laudisio (2019)
10.1093/ehjcvp/pvz053
Breaking the rules for studies using real-world observational data: The case of direct-acting anticoagulants and antiepileptic drugs.
Joshua D. K. Brown (2019)
10.1016/j.jacc.2018.03.023
Oral Anticoagulation in Patients With Liver Disease.
Arman Qamar (2018)
10.1093/ehjcvp/pvz054
Response to the "Breaking the rules for studies using real-world observational data: The case of direct acting anticoagulants and antiepileptic drugs by Dr. Brown et al."
Chun-li Wang (2019)
10.1007/s40262-020-00879-x
Drug–Drug Interactions with Direct Oral Anticoagulants
Kathrin I. Foerster (2020)
10.1016/j.ejpb.2020.01.002
Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Elodie Jacqueroux (2020)
10.4067/S0034-98872019000100073
[Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
Andrés Enríquez (2019)
10.1016/j.ajem.2019.12.049
Pain in the hip: Spontaneous retroperitoneal hemorrhage in an elderly patient on apixaban.
Adil Khan (2019)
10.1111/jgs.15982
Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation.
Smrithi Sukumar (2019)
10.1016/j.ejim.2019.10.026
Practical use of Direct Oral Anti Coagulants (DOACs) in the older persons with atrial fibrillation.
Mario Bo (2019)
10.1007/s40256-019-00350-8
Association Between Digoxin Use and Adverse Outcomes Among Patients in the Chinese Atrial Fibrillation Registry
Ying Gao (2019)
10.3389/fneur.2018.01067
Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs
Alessandro Galgani (2018)
10.14740/jocmr3394w
A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge
James A. Josyln (2018)
10.1007/s00392-019-01526-7
Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case–control studies
Kathrin Jobski (2019)
10.3389/fphar.2018.00491
Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect
Zhi-chun Gu (2018)
Anticoagulación oral en pacientes con hepatopatía
Arman Qamar (2018)
10.3390/jpm8030022
Warfarin: The End or the End of One Size Fits All Therapy?
Munir Pirmohamed (2018)
10.1136/bmjopen-2018-026645
Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016
Géric Maura (2019)
10.1128/AAC.02275-17
Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.
Payal P Kakadiya (2018)
10.1007/s40256-018-0310-3
Assessment of Non-vitamin K Oral Anticoagulants Use in a Tertiary Care Center in the USA: A Chart Review of 909 Patients
Marwan Sheikh-Taha (2018)
10.1016/j.jacc.2019.12.068
Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week.
Barbara S Wiggins (2020)
10.1080/17512433.2019.1637733
Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy
Edwin Lam (2019)
10.1002/cpt.1376
A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data.
Katsiaryna Bykov (2019)
10.1111/fcp.12504
In vitro assessment of P-gp and BCRP transporters-mediated drug-drug interactions of riociguat with direct oral anticoagulants.
Elodie Jacqueroux (2019)
10.1001/jama.2017.20850
Drug Interactions With Non-Vitamin K Oral Anticoagulants.
Nan Wang (2018)
10.1016/j.urology.2019.06.004
Shorter hospital stay and fewer hospitalisations in patients with visible haematuria on direct oral anticoagulants compared to on vitamin K antagonists.
Martin Müller (2019)
10.1136/jim-2019-001209
Statin use and the risk of renal cell carcinoma: national cohort study
Yu-Ching Chou (2019)
10.1001/jamainternmed.2020.1835
Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants.
Kevin Michael Andrew Hill (2020)
10.1038/s41574-018-0137-7
Post-transplant diabetes mellitus in patients with solid organ transplants
Trond Jenssen (2019)
A national audit on the utilisation and documentation of dabigatran checklist for patients initiated on dabigatran.
Gallegos Doris (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar